Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19463634 | 0.83 | ADAMTS4 (0.44) | ADORA2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25321212 | 0.82 | KCNH2 (0.44) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22242035 | 0.79 | ADORA2A (0.41) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL17247586 | 0.78 | CYP1A2 (0.40) | ADORA2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30193023 | 0.76 | ADORA2A (0.40) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL4714316 | 0.76 | CYP1A2 (0.35) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4470267 | 0.76 | MEN1 (0.39) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24347486 | 0.75 | HCRTR1 (0.42) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL536722 | 0.75 | HCRTR1 (0.41) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL12335121 | 0.74 | CYP1A2 (0.38) | CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4122927-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | HCRTR1 1495/4885HCRTR2 1086/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.